Moxifloxacin/dexamethasone - Ocumension Therapeutics
Alternative Names: Dexamethasone/moxifloxacin - Ocumension Therapeutics; Moxifloxacin-dexamethasone sodium phosphate; OT-601-CLatest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Ocumension Therapeutics
- Class Anti-inflammatories; Aza compounds; Fluorinated steroids; Pregnadienetriols; Quinolines
- Mechanism of Action DNA gyrase inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postoperative inflammation
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Postoperative-inflammation in China (Ophthalmic, Drops)
- 10 Jul 2020 Preclinical trials in Postoperative inflammation in China (Ophthalmic)
- 10 Jul 2020 Ocumension Therapeutics plans a clinical trial for Postoperative inflammation in China